scispace - formally typeset
K

Kate M Bubar

Researcher at University of Colorado Boulder

Publications -  10
Citations -  924

Kate M Bubar is an academic researcher from University of Colorado Boulder. The author has contributed to research in topics: Population & Vaccination. The author has an hindex of 6, co-authored 9 publications receiving 444 citations. Previous affiliations of Kate M Bubar include Los Alamos National Laboratory & Colorado School of Mines.

Papers
More filters
Journal ArticleDOI

Model-informed COVID-19 vaccine prioritization strategies by age and serostatus.

TL;DR: This article used a mathematical model to compare five age-stratified prioritization strategies for the SARS-CoV-2 vaccine and found that individual-level serological tests to redirect doses to seronegative individuals improved the marginal impact of each dose while potentially reducing existing inequities in COVID-19 impact.
Posted ContentDOI

Model-informed COVID-19 vaccine prioritization strategies by age and serostatus

TL;DR: A model-informed approach to vaccine prioritization is employed that evaluates the impact of prioritization strategies on cumulative incidence and mortality and accounts for population factors such as age, contact structure, and seroprevalence, and vaccine factors including imperfect and age-varying efficacy.
Journal ArticleDOI

Estimating SARS-CoV-2 seroprevalence and epidemiological parameters with uncertainty from serological surveys.

TL;DR: A flexible framework that integrates uncertainty from test characteristics, sample size, and heterogeneity in seroprevalence across tested subpopulations to compare estimates from sampling schemes is used and it is found that sampling schemes informed by demographics and contact networks outperform uniform sampling.
Posted ContentDOI

Estimating SARS-CoV-2 seroprevalence and epidemiological parameters with uncertainty from serological surveys

TL;DR: In this paper, the authors used a flexible framework that integrates uncertainty from test characteristics, sample size, and heterogeneity in seroprevalence across tested subpopulations to compare estimates from sampling schemes.